Enobia developed the super-orphan drug Strensiq™ (asfotase alfa) for the treatment of Hypophosphatasia. Enobia was acquired by Alexion for $1.1 billion in 2022.
Location
Montreal, Canada
History
Acquired by Alexion Pharmaceuticals for $1.1 billion in 2022
